X
Lundbeck craters as resistant schizophrenia drug fails phase III
https://pharmaphorum.com/news/lundbeck-craters-as-resistant-schizophrenia-drug-fails-phase-iii/
Lundbeck
Bad week for dementia R&D after Axovant howler and another failed trial
Axovant misreports trial results, Lundbeck Alzheimer’s drug fails
Swedish biotech Hansa shocked by CEO’s sudden death
Ulf Wiinberg becomes acting CEO
Lundbeck trial investigates genetic causes of depression
New study with 23andMe and Milken Institute looks to determine causes of depression.
Lundbeck enlists IBM Watson to aid psychiatric drug research
Collaboration will initially focus on Parkinson’s disease and schizophrenia.
Lundbeck epilepsy injection approved in US
New carbamazepine formulation when oral dosing not feasible.
